FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204332334> ?p ?o ?g. }

• W3204332334 abstract "Scleroderma, or systemic sclerosis, is a multi-organ connective tissue disease resulting in fibrosis of the skin, heart, and lungs with no effective treatment. Endocannabinoids acting via cannabinoid-1 receptors (CB1R) and increased activity of inducible NO synthase (iNOS) promote tissue fibrosis including skin fibrosis, and joint targeting of these pathways may improve therapeutic efficacy. Recently, we showed that in mouse models of liver, lung and kidney fibrosis, treatment with a peripherally restricted hybrid CB1R/iNOS inhibitor (MRI-1867) yields greater anti-fibrotic efficacy than inhibiting either target alone. Here, we evaluated the therapeutic efficacy of MRI-1867 in bleomycin-induced skin fibrosis. Skin fibrosis was induced in C57BL/6J (B6) and Mdr1a/b-Bcrp triple knock-out (KO) mice by daily subcutaneous injections of bleomycin (2 IU/100 µL) for 28 days. Starting on day 15, mice were treated for 2 weeks with daily oral gavage of vehicle or MRI-1867. Skin levels of MRI-1867 and endocannabinoids were measured by mass spectrometry to assess target exposure and engagement by MRI-1867. Fibrosis was characterized histologically by dermal thickening and biochemically by hydroxyproline content. We also evaluated the potential increase of drug-efflux associated ABC transporters by bleomycin in skin fibrosis, which could affect target exposure to test compounds, as reported in bleomycin-induced lung fibrosis. Bleomycin-induced skin fibrosis was comparable in B6 and Mdr1a/b-Bcrp KO mice. However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 µM) than in Mdr1a/b-Bcrp KO mice (8.8 µM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin. Furthermore, the endocannabinoids anandamide and 2-arachidonylglycerol were elevated 2-4-fold in the fibrotic vs. control skin in both mouse strains. MRI-1867 treatment attenuated bleomycin-induced established skin fibrosis and the associated increase in endocannabinoids in Mdr1a/b-Bcrp KO mice but not in B6 mice. We conclude that combined inhibition of CB1R and iNOS is an effective anti-fibrotic strategy for scleroderma. As bleomycin induces an artifact in testing antifibrotic drug candidates that are substrates of drug-efflux transporters, using Mdr1a/b-Bcrp KO mice for preclinical testing of such compounds avoids this pitfall." @default.
• W3204332334 created "2021-10-11" @default.
• W3204332334 creator A5016103616 @default.
• W3204332334 creator A5016112596 @default.
• W3204332334 creator A5022723914 @default.
• W3204332334 creator A5026132845 @default.
• W3204332334 creator A5030040763 @default.
• W3204332334 creator A5084767391 @default.
• W3204332334 date "2021-09-28" @default.
• W3204332334 modified "2023-09-26" @default.
• W3204332334 title "Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis" @default.
• W3204332334 cites W1789400669 @default.
• W3204332334 cites W1967973854 @default.
• W3204332334 cites W1968250218 @default.
• W3204332334 cites W1974662051 @default.
• W3204332334 cites W1993692236 @default.
• W3204332334 cites W2001427377 @default.
• W3204332334 cites W2011785203 @default.
• W3204332334 cites W2018964836 @default.
• W3204332334 cites W2024880230 @default.
• W3204332334 cites W203320535 @default.
• W3204332334 cites W2051061580 @default.
• W3204332334 cites W2053874206 @default.
• W3204332334 cites W2079982637 @default.
• W3204332334 cites W2083672320 @default.
• W3204332334 cites W2087587748 @default.
• W3204332334 cites W2089714176 @default.
• W3204332334 cites W2090548255 @default.
• W3204332334 cites W2091510740 @default.
• W3204332334 cites W2094409327 @default.
• W3204332334 cites W2104007067 @default.
• W3204332334 cites W2104497132 @default.
• W3204332334 cites W2107174531 @default.
• W3204332334 cites W2108588832 @default.
• W3204332334 cites W2120720610 @default.
• W3204332334 cites W2122310716 @default.
• W3204332334 cites W2127541742 @default.
• W3204332334 cites W2130820483 @default.
• W3204332334 cites W2149839143 @default.
• W3204332334 cites W2163926545 @default.
• W3204332334 cites W2164988046 @default.
• W3204332334 cites W2166711401 @default.
• W3204332334 cites W2170281217 @default.
• W3204332334 cites W2171335364 @default.
• W3204332334 cites W2177675794 @default.
• W3204332334 cites W2198496807 @default.
• W3204332334 cites W2203263917 @default.
• W3204332334 cites W2396463232 @default.
• W3204332334 cites W2412043283 @default.
• W3204332334 cites W2496524534 @default.
• W3204332334 cites W2534661417 @default.
• W3204332334 cites W2576890041 @default.
• W3204332334 cites W2606597561 @default.
• W3204332334 cites W2617679854 @default.
• W3204332334 cites W2751534001 @default.
• W3204332334 cites W2920488973 @default.
• W3204332334 cites W2968596070 @default.
• W3204332334 cites W2971347355 @default.
• W3204332334 cites W3000725886 @default.
• W3204332334 cites W3048858461 @default.
• W3204332334 cites W3149782815 @default.
• W3204332334 cites W3184212520 @default.
• W3204332334 cites W4252346179 @default.
• W3204332334 doi "https://doi.org/10.3389/fendo.2021.744857" @default.
• W3204332334 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8505776" @default.
• W3204332334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34650521" @default.
• W3204332334 hasPublicationYear "2021" @default.
• W3204332334 type Work @default.
• W3204332334 sameAs 3204332334 @default.
• W3204332334 citedByCount "9" @default.
• W3204332334 countsByYear W32043323342021 @default.
• W3204332334 countsByYear W32043323342022 @default.
• W3204332334 countsByYear W32043323342023 @default.
• W3204332334 crossrefType "journal-article" @default.
• W3204332334 hasAuthorship W3204332334A5016103616 @default.
• W3204332334 hasAuthorship W3204332334A5016112596 @default.
• W3204332334 hasAuthorship W3204332334A5022723914 @default.
• W3204332334 hasAuthorship W3204332334A5026132845 @default.
• W3204332334 hasAuthorship W3204332334A5030040763 @default.
• W3204332334 hasAuthorship W3204332334A5084767391 @default.
• W3204332334 hasBestOaLocation W32043323341 @default.
• W3204332334 hasConcept C126322002 @default.
• W3204332334 hasConcept C142724271 @default.
• W3204332334 hasConcept C2776232574 @default.
• W3204332334 hasConcept C2776694085 @default.
• W3204332334 hasConcept C2779797417 @default.
• W3204332334 hasConcept C2780559512 @default.
• W3204332334 hasConcept C2781244666 @default.
• W3204332334 hasConcept C71924100 @default.
• W3204332334 hasConcept C98274493 @default.
• W3204332334 hasConceptScore W3204332334C126322002 @default.
• W3204332334 hasConceptScore W3204332334C142724271 @default.
• W3204332334 hasConceptScore W3204332334C2776232574 @default.
• W3204332334 hasConceptScore W3204332334C2776694085 @default.
• W3204332334 hasConceptScore W3204332334C2779797417 @default.
• W3204332334 hasConceptScore W3204332334C2780559512 @default.
• W3204332334 hasConceptScore W3204332334C2781244666 @default.
• W3204332334 hasConceptScore W3204332334C71924100 @default.
• W3204332334 hasConceptScore W3204332334C98274493 @default.
• W3204332334 hasFunder F4320337330 @default.

• next